RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
-13.4%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$4.83B
AUM Growth
+$4.83B
(-29%)
Cap. Flow
-$900M
Cap. Flow
% of AUM
-18.64%
Top 10 Holdings %
Top 10 Hldgs %
38.68%
Holding
126
New
2
Increased
20
Reduced
30
Closed
20
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$52M |
| 2 |
C4 Therapeutics
CCCC
|
$49.4M |
| 3 |
Masimo
MASI
|
$40.4M |
| 4 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$24.4M |
| 5 |
TSVT
2seventy bio
TSVT
|
$21M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$423M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$112M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$98.5M |
| 4 |
iTeos Therapeutics
ITOS
|
$60M |
| 5 |
IDEAYA Biosciences
IDYA
|
$59.6M |
Sector Composition
| 1 | Healthcare | 99.3% |
| 2 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alnylam Pharmaceuticals
ALNY
$58.5B
| $275M | 5.69% | 1,683,362 -292,517 | -15% | -$47.8M |
|
2
Rocket Pharmaceuticals
RCKT
$354M
| $251M | 5.19% | 15,802,802 | – | – |
|
3
Thermo Fisher Scientific
TMO
$186B
| $220M | 4.56% | 373,000 -62,500 | -14% | -$36.9M |
|
4
PTC Therapeutics
PTCT
$3.92B
| $195M | 4.03% | 5,221,228 -72,738 | -1% | -$2.71M |
|
5
Illumina
ILMN
$15.8B
| $178M | 3.68% | 509,375 +18,976 | +4% | +$6.63M |
|
|
6
Masimo
MASI
$7.59B
| $164M | 3.4% | 1,127,593 +277,622 | +33% | +$40.4M |
|
7
Establishment Labs
ESTA
$1.2B
| $156M | 3.23% | 2,319,138 | – | – |
|
8
Vericel Corp
VCEL
$1.83B
| $154M | 3.18% | 4,017,570 -500,000 | -11% | -$19.1M |
|
9
Penumbra
PEN
$10.6B
| $148M | 3.06% | 665,871 +45,000 | +7% | +$10M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $128M | 2.66% | 1,561,497 | – | – |
|
11
Globus Medical
GMED
$8.27B
| $124M | 2.57% | 1,682,291 +11,480 | +0.7% | +$847K |
|
12
Tandem Diabetes Care
TNDM
$845M
| $117M | 2.42% | 1,004,936 -155,798 | -13% | -$18.1M |
|
|
13
Protagonist Therapeutics
PTGX
$3.67B
| $114M | 2.35% | 4,794,499 +2,194,677 | +84% | +$52M |
|
|
14
C4 Therapeutics
CCCC
$185M
| $110M | 2.28% | 4,531,982 +2,037,017 | +82% | +$49.4M |
|
|
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
| $109M | 2.26% | 1,743,864 -200,000 | -10% | -$12.5M |
|
16
argenx
ARGX
$43.6B
| $106M | 2.2% | 336,978 +19,531 | +6% | +$6.16M |
|
|
CUTR
17
DELISTED
Cutera, Inc.
CUTR
| $105M | 2.18% | 1,526,263 +129,200 | +9% | +$8.91M |
|
18
Celldex Therapeutics
CLDX
$1.47B
| $105M | 2.17% | 3,084,215 -837,364 | -21% | -$28.5M |
|
|
RXDX
19
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $104M | 2.16% | 2,757,947 -506,084 | -16% | -$19.1M |
|
20
Ultragenyx Pharmaceutical
RARE
$2.89B
| $99.7M | 2.06% | 1,373,284 | – | – |
|
21
Cytokinetics
CYTK
$4.23B
| $94.3M | 1.95% | 2,561,182 | – | – |
|
22
Avidity Biosciences
RNA
$5.99B
| $88.6M | 1.83% | 4,795,000 | – | – |
|
23
Fulcrum Therapeutics
FULC
$351M
| $85.4M | 1.77% | 3,611,194 -255,678 | -7% | -$6.05M |
|
24
PMV Pharmaceuticals
PMVP
$74.2M
| $80.6M | 1.67% | 3,872,154 +891,194 | +30% | +$18.6M |
|
25
Natera
NTRA
$23.1B
| $78M | 1.61% | 1,917,283 +55,049 | +3% | +$2.24M |
|